LongevityLOF-NLNCT06374069
Longevity Families of the Netherlands
An observational study of Longevity and Familial Longevity, run by Leiden University Medical Center at 1 site in Netherlands.
Trial summary
The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Read more about this study
- Who is it for?
- Ages 75 years and olderHealthy volunteers can take part
- Conditions the study is for
- Longevity, Familial Longevity, Extreme Longevity
- How many people
- 600 participants
- Where
- 1 siteNetherlands
- Study dates
- 11 Sep 2023to Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 75 years and older
- All sexes
- Healthy volunteers accepted
- Older adult
Study population: Dutch Caucasian descent: Ages 75 and older, with siblings enriched for familial longevity, and individuals without a history of familial longevity
Who may be able to join
- Siblings of Dutch Caucasian descent age 75+ enriched for familial longevity
- Individuals of Dutch Caucasian descent age 75+ who are not enriched for familial longevity
Who cannot join
- -
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
Leiden University Medical Center
Leiden, South Holland, 2333ZA
About this study
The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.
The purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component.
- Conditions
- Longevity, Familial Longevity, Extreme Longevity, Aging
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Cases - Enriched for familial longevity | Siblings of dutch Caucasian descent ages 75 and older | |
| Controls - Non-enriched for familial longevity | Individuals of dutch Caucasian descent ages 75 and older solely in their family. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Identifying the genetic variants of Familial Longevity
To identify gene variants associated with healthy aging and protection from (multi)morbidity
Measured: through study completion, an average of 2 years
Secondary outcomes (1)
Studying the environmental factor of Familial Longevity through questionnaires and its interaction with the genetic component
To study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component
Measured: through study completion, an average of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2024
- Study start11 Sep 2023
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for LongevityStudies of the same condition, open and under way.
- More trials run by Leiden University Medical CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Family based
- Time perspective
- Cross-sectional
- Enrolment
- 600 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Leiden University Medical Center
- Sponsor type
- University, hospital or other
- Collaborators
- Jacobijn Gussekloo, Prof. dr., Simon P. Mooijaart, Prof. dr.
- Responsible party
- Principal investigator, Eline Slagboom, Leiden University Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06374069
- Sponsor's protocol ID
- NL81887.058.23
- Acronym
- LOF-NL
- Status last verified
- Sep 2025
- First submitted
- 20 Mar 2024
- Last updated
- 26 Aug 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 26 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Longevity Families of the Netherlands
- ClinicalTrials.gov ID
- NCT06374069
- Acronym / sponsor ID
- LOF-NL / NL81887.058.23
- Conditions
- Longevity, Familial Longevity, Extreme Longevity, Aging
- Study type
- Observational
- Recruitment status
- Active, not recruiting
- Enrolment
- 600 participants (estimated)
- Lead sponsor
- Leiden University Medical CenterUniversity, hospital or other
- Collaborators
- Jacobijn Gussekloo, Prof. dr., Simon P. Mooijaart, Prof. dr.
- Study start
- 11 Sep 2023 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 18 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The demographic life expectancy enhancement of the past 150 years imposes an urgent challenge in Western and economically growing societies to stimulate the healthy lifespan that is lagging behind. Families surviving into exceptionally high ages (longevity) in good physical and mental health illustrate that this is physiologically possible. Such families harbor cross generational socio-genetic mechanisms that mediate healthy aging and protection from (multi)morbidity.
The purpose of our research is: to identify gene variants associated with healthy aging and protection from (multi)morbidity; to study the social-, environment- and behavioral factors of familial longevity, their role in (multi-)morbidity and its interaction with the genetic component.
Study design
- Observational model
- Family based
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cases - Enriched for familial longevity | – | –Siblings of dutch Caucasian descent ages 75 and older |
| Controls - Non-enriched for familial longevity | – | –Individuals of dutch Caucasian descent ages 75 and older solely in their family. |
Who may qualify
- Ages
- 75 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Older adult
- Study population
- Dutch Caucasian descent: Ages 75 and older, with siblings enriched for familial longevity, and individuals without a history of familial longevity
Key inclusion criteria (2 listed)
- Siblings of Dutch Caucasian descent age 75+ enriched for familial longevity
- Individuals of Dutch Caucasian descent age 75+ who are not enriched for familial longevity
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Identifying the genetic variants of Familial Longevity
Time frame: through study completion, an average of 2 years
To identify gene variants associated with healthy aging and protection from (multi)morbidity
1 secondary outcome
Studying the environmental factor of Familial Longevity through questionnaires and its interaction with the genetic component
Time frame: through study completion, an average of 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Aug 2026.
Related trials for Longevity
Not yet recruitingPhase 2
Validation & Intervention Testing for Aging, Longevity and Healthspan
Aging, Functional Decline
Not yet recruiting
Fecal Microbiota Transplantation (FMT) to Slow Biological Aging
Aging, Healthy, Aging and Cognitive Health
Enrolling by invitationPhase 2
Tirzepatide and Organ-specific Biological Aging
Longevity, Preventive Medicine
Not yet recruitingObservational study
Effect of Filter Lifespan in CRRT on New Infections in Critically Ill Patients With AKI
Acute Kidney Injury
Active, not recruiting
Iterative Design Trial to Assess Dietary Supplements and Other Aging-targeted Therapies
Aging, Longevity
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Longevity and Familial Longevity, run by Leiden University Medical Center at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 26 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Identifying the genetic variants of Familial Longevity (time frame: through study completion, an average of 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Aug 2026.